Literature DB >> 12049723

CD154-dependent priming of diabetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells.

Abdelaziz Amrani1, Pau Serra, Jun Yamanouchi, Bingye Han, Shari Thiessen, Joan Verdaguer, Pere Santamaria.   

Abstract

We followed the fate of K(d)- or I-A(g7)-restricted beta cell-autoreactive T cells in monoclonal TCR-transgenic NOD mice expressing or lacking CD154. 8.3-NOD.RAG-2(-/-)/CD154(-/-) mice, which bear autoreactive CD8(+) T cells, developed diabetes with the same incidence and tempo as 8.3-NOD.RAG-2(-/-)/CD154(+) mice. Recruitment of CD154(-/-) 8.3-CD8(+) CTL was accelerated by CD154(+)CD4(+) T cells, by expression of a B7.1 transgene in beta cells or by treatment of the mice with CpG-DNA or an agonistic anti-CD40 antibody. In contrast, the autoreactive CD4(+) T cells maturing in 4.1-NOD.RAG-2(-/-) mice lost their diabetogenic potential if they lacked CD154, even in the presence of CD154(+)CD4(+) T cells, B7.1 molecules on beta cells, CpG-DNA treatment, or systemic CD40 ligation. These results demonstrate the existence of a novel, CD154-dependent pathway of CD4(+) T cell activation that is independent of CD40-mediated activation of APCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12049723     DOI: 10.1016/s1074-7613(02)00315-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  13 in total

Review 1.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

2.  Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity.

Authors:  Jun Yamanouchi; Dan Rainbow; Pau Serra; Sarah Howlett; Kara Hunter; Valerie E S Garner; Andrea Gonzalez-Munoz; Jan Clark; Riitta Veijola; Rose Cubbon; Show-Ling Chen; Raymond Rosa; Anne Marie Cumiskey; David V Serreze; Simon Gregory; Jane Rogers; Paul A Lyons; Barry Healy; Luc J Smink; John A Todd; Laurence B Peterson; Linda S Wicker; Pere Santamaria
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

Review 3.  Of the multiple mechanisms leading to type 1 diabetes, T cell receptor revision may play a prominent role (is type 1 diabetes more than a single disease?).

Authors:  D H Wagner
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

Review 4.  Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.

Authors:  Tijana Martinov; Brian T Fife
Journal:  Ann N Y Acad Sci       Date:  2019-04-26       Impact factor: 5.691

5.  CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes.

Authors:  Gisela M Vaitaitis; Dan M Waid; Martin G Yussman; David H Wagner
Journal:  Immunology       Date:  2017-06-19       Impact factor: 7.397

Review 6.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes.

Authors:  Catrin M McGregor; Stephen P Schoenberger; E Allison Green
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

Review 8.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

9.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells.

Authors:  Hélène Bour-Jordan; Benoît L Salomon; Heather L Thompson; Gregory L Szot; Matthew R Bernhard; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

10.  A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.

Authors:  Gisela M Vaitaitis; Michael H Olmstead; Dan M Waid; Jessica R Carter; David H Wagner
Journal:  Diabetologia       Date:  2014-08-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.